Effects of Antitumor Necrosis Factor Therapy on Osteoprotegerin, Neopterin, and sRANKL Concentrations in Patients with Rheumatoid Arthritis

Table 1

Median (and interquartile ranges in brackets) number of tender and swollen joints and DAS28 score as well as the median concentrations of investigated lab parameters before and under adalimumab therapy ().

	Baseline	After adalimumab therapy, week 12	value
DAS28 score	5.7 (5.4–6.3)	3.1 (2.4–3.7)	<0.001
Tender joints	12 (7–17)	0 (0–2)	<0.001
Swollen joints	9 (6–11)	1 (0–4)	<0.001
Neopterin (nM)	7.6 (5.5–9.4)	8.2 (6.0–13.0)	n.s.
C-reactive protein (mg/L)	13.1 (6.2–31.1)	5.8 (0.9–16.3)	0.058
ESR (mm/h)	31 (17–51)	23 (11–41)	n.s.
Osteoprotegerin (pM)	4.5 (4.0–5.3)	4.1 (3.3–4.6)	0.015
sRANKL (pM)	0.89 (0.44–1.08)	0.80 (0.38–1.47)	n.s.
sRANKL/OPG	0.17 (0.1–0.28)	0.19 (0.8–0.35)	n.s.